233 related articles for article (PubMed ID: 17690588)
1. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
Martínez E; Gatell JM
AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
[No Abstract] [Full Text] [Related]
2. Switch study of nevirapine.
AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
[No Abstract] [Full Text] [Related]
3. [Nevirapine (Viramune): a new HIV inhibitor].
De Wit S; Sternon J; Clumeck N
Rev Med Brux; 1999 Apr; 20(2):95-9. PubMed ID: 10335104
[TBL] [Abstract][Full Text] [Related]
4. [Combined antiretroviral therapy with nevirapine of HIV-infected adults].
Kravchenko AV
Ter Arkh; 2004; 76(11):68-71. PubMed ID: 15658542
[No Abstract] [Full Text] [Related]
5. HIV drug now approved for use with protease inhibitors.
Nurse Pract; 1998 Oct; 23(10):89. PubMed ID: 9805335
[No Abstract] [Full Text] [Related]
6. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
[TBL] [Abstract][Full Text] [Related]
7. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
[No Abstract] [Full Text] [Related]
8. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
[TBL] [Abstract][Full Text] [Related]
9. Protease inhibitor-sparing regimen suppresses HIV.
AIDS Patient Care STDS; 1998 Dec; 12(12):940. PubMed ID: 11362068
[No Abstract] [Full Text] [Related]
10. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Chang SY; Lin SW; Hung CC
Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
[No Abstract] [Full Text] [Related]
11. Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Leyes M; Pedrol E; Force L; de Lazzari E; Gatell JM
AIDS; 2007 Jan; 21(3):367-9. PubMed ID: 17255745
[TBL] [Abstract][Full Text] [Related]
12. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
[No Abstract] [Full Text] [Related]
13. Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
Yozviak JL; Doerfler RE; Woodward WC
Clin Infect Dis; 2002 Feb; 34(4):547-50. PubMed ID: 11797185
[TBL] [Abstract][Full Text] [Related]
14. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
Cuzin L; Allavena C; Morlat P; Dellamonica P
AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
[TBL] [Abstract][Full Text] [Related]
15. Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children.
Pensieroso S; Romiti ML; Palma P; Castelli-Gattinara G; Bernardi S; Freda E; Rossi P; Cancrini C
AIDS; 2006 Sep; 20(14):1893-6. PubMed ID: 16954733
[TBL] [Abstract][Full Text] [Related]
16. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
Müller AD; Myer L; Jaspan H
Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
Shaw AJ; McLean KA
Int J STD AIDS; 1999 Jun; 10(6):417-8. PubMed ID: 10414887
[No Abstract] [Full Text] [Related]
18. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
[No Abstract] [Full Text] [Related]
19. Effectiveness and durability of non-nucleoside reverse transcriptase inhibitor-based therapy in HIV clinical practice.
Kan VL
AIDS; 2007 Apr; 21(7):880-2. PubMed ID: 17415048
[No Abstract] [Full Text] [Related]
20. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
